Acquired resistance to pd-1/pd-l1 blockade in lung cancer: Mechanisms and patterns of failure

Ranjan Pathak; Rebecca R. Pharaon; Atish Mohanty; Victoria M. Villaflor; Ravi Salgia; Erminia Massarelli

doi:10.3390/cancers12123851

Acquired resistance to pd-1/pd-l1 blockade in lung cancer: Mechanisms and patterns of failure

Ranjan Pathak, Rebecca R. Pharaon, Atish Mohanty, Victoria M. Villaflor, Ravi Salgia, Erminia Massarelli^*

^*Corresponding author for this work

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Review article › peer-review

24 Scopus citations

Abstract

Immunotherapy is now the preferred treatment for most lung cancer patients. It is used to treat unresectable stage III non-small-cell lung cancer and is the first-line therapy for non-oncogene-driven advanced/metastatic non-small-cell lung cancer patients (either alone or in combination with chemotherapy). Unfortunately, most patients that respond initially to immunotherapy develop resistance over time, thus limiting the durability of immunotherapy. A better understanding of the mechanisms of acquired resistance is urgently needed to expand the benefit of immunotherapy in lung cancer patients. This review aims to summarize the mechanisms and clinical outcomes of acquired resistance of anti-PD-1/PD-L1 therapies in non-small-cell lung cancer patients.

Original language	English (US)
Article number	3851
Pages (from-to)	1-13
Number of pages	13
Journal	Cancers
Volume	12
Issue number	12
DOIs	https://doi.org/10.3390/cancers12123851
State	Published - Dec 2020

Keywords

Acquired resistance
Immune checkpoint inhibitors
Immunotherapy
Lung cancer
PD-1
PD-L1

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/cancers12123851

Cite this

@article{93863631e1d041e1b36272ff5ac65524,

title = "Acquired resistance to pd-1/pd-l1 blockade in lung cancer: Mechanisms and patterns of failure",

abstract = "Immunotherapy is now the preferred treatment for most lung cancer patients. It is used to treat unresectable stage III non-small-cell lung cancer and is the first-line therapy for non-oncogene-driven advanced/metastatic non-small-cell lung cancer patients (either alone or in combination with chemotherapy). Unfortunately, most patients that respond initially to immunotherapy develop resistance over time, thus limiting the durability of immunotherapy. A better understanding of the mechanisms of acquired resistance is urgently needed to expand the benefit of immunotherapy in lung cancer patients. This review aims to summarize the mechanisms and clinical outcomes of acquired resistance of anti-PD-1/PD-L1 therapies in non-small-cell lung cancer patients.",

keywords = "Acquired resistance, Immune checkpoint inhibitors, Immunotherapy, Lung cancer, PD-1, PD-L1",

author = "Ranjan Pathak and Pharaon, {Rebecca R.} and Atish Mohanty and Villaflor, {Victoria M.} and Ravi Salgia and Erminia Massarelli",

note = "Publisher Copyright: {\textcopyright} 2020 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2020",

month = dec,

doi = "10.3390/cancers12123851",

language = "English (US)",

volume = "12",

pages = "1--13",

journal = "Cancers",

issn = "2072-6694",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "12",

}

TY - JOUR

T1 - Acquired resistance to pd-1/pd-l1 blockade in lung cancer

T2 - Mechanisms and patterns of failure

AU - Pathak, Ranjan

AU - Pharaon, Rebecca R.

AU - Mohanty, Atish

AU - Villaflor, Victoria M.

AU - Salgia, Ravi

AU - Massarelli, Erminia

PY - 2020/12

Y1 - 2020/12

N2 - Immunotherapy is now the preferred treatment for most lung cancer patients. It is used to treat unresectable stage III non-small-cell lung cancer and is the first-line therapy for non-oncogene-driven advanced/metastatic non-small-cell lung cancer patients (either alone or in combination with chemotherapy). Unfortunately, most patients that respond initially to immunotherapy develop resistance over time, thus limiting the durability of immunotherapy. A better understanding of the mechanisms of acquired resistance is urgently needed to expand the benefit of immunotherapy in lung cancer patients. This review aims to summarize the mechanisms and clinical outcomes of acquired resistance of anti-PD-1/PD-L1 therapies in non-small-cell lung cancer patients.

AB - Immunotherapy is now the preferred treatment for most lung cancer patients. It is used to treat unresectable stage III non-small-cell lung cancer and is the first-line therapy for non-oncogene-driven advanced/metastatic non-small-cell lung cancer patients (either alone or in combination with chemotherapy). Unfortunately, most patients that respond initially to immunotherapy develop resistance over time, thus limiting the durability of immunotherapy. A better understanding of the mechanisms of acquired resistance is urgently needed to expand the benefit of immunotherapy in lung cancer patients. This review aims to summarize the mechanisms and clinical outcomes of acquired resistance of anti-PD-1/PD-L1 therapies in non-small-cell lung cancer patients.

KW - Acquired resistance

KW - Immune checkpoint inhibitors

KW - Immunotherapy

KW - Lung cancer

KW - PD-1

KW - PD-L1

UR - http://www.scopus.com/inward/record.url?scp=85098283452&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85098283452&partnerID=8YFLogxK

U2 - 10.3390/cancers12123851

DO - 10.3390/cancers12123851

M3 - Review article

C2 - 33419311

AN - SCOPUS:85098283452

SN - 2072-6694

VL - 12

SP - 1

EP - 13

JO - Cancers

JF - Cancers

IS - 12

M1 - 3851

ER -

Acquired resistance to pd-1/pd-l1 blockade in lung cancer: Mechanisms and patterns of failure

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this